 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...255256257258259260261262263264265266267» |
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Dec 8, 2013
P1, N=62, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Recruiting
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (clinicaltrials.gov) - Dec 4, 2013
P2, N=140, Recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed: Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer (clinicaltrials.gov) - Dec 4, 2013
P=N/A, N=18, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Xalkori (crizotinib) / Pfizer
New P1 trial, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov) - Nov 26, 2013
P1, N=46, Recruiting, Sponsor: University of Utah
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial: A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (clinicaltrials.gov) - Nov 25, 2013
P1, N=24, Not yet recruiting, Sponsor: Duke University
- || denenicokin (BMS-982470) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy, Metastases: Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (clinicaltrials.gov) - Nov 25, 2013
P1, N=150, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Yervoy (ipilimumab) / BMS
Surgery: E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - Nov 24, 2013
P3, N=1500, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=1000 --> 1500
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - Nov 21, 2013
P2, N=18, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| Oncopore (ruxotemitide) / Verrica
Enrollment open, Monotherapy: LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (clinicaltrials.gov) - Nov 20, 2013
P1, N=80, Recruiting, Sponsor: Lytix Biopharma AS
N=1000 --> 1500 Not yet recruiting --> Recruiting
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Nov 20, 2013
P2, N=92, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial suspension, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=69, Suspended, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Suspended
- Yervoy (ipilimumab) / BMS
New P2 trial, Combination therapy, Metastases: Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients (clinicaltrials.gov) - Nov 18, 2013
P2, N=15, Recruiting, Sponsor: Sheba Medical Center
- ||| Oncopore (ruxotemitide) / Verrica
New P1 trial, Monotherapy: LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (clinicaltrials.gov) - Nov 14, 2013
P1, N=80, Recruiting, Sponsor: Lytix Biopharma AS
- Tarvacin (bavituximab) / OncXerna Therap, Yervoy (ipilimumab) / BMS
New P1 trial, Metastases: A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (clinicaltrials.gov) - Nov 12, 2013
P1, N=24, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- Yervoy (ipilimumab) / BMS
Enrollment open: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 30, 2013
P1/2, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg.
Enrollment closed, Metastases: CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (clinicaltrials.gov) - Oct 30, 2013
P2, N=29, Active, not recruiting, Sponsor: Bhardwaj, Nina, M.D.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Selectikine (EMD 521873) / EMD Serono
New P2 trial, Combination therapy, Metastases: EMR 062235-005: MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (clinicaltrials.gov) - Oct 29, 2013
P2, N=86, Recruiting, Sponsor: EMD Serono
- Yervoy (ipilimumab) / BMS
New P1/2 trial, Metastases: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Oct 24, 2013
P1/2, N=40, Recruiting, Sponsor: University of Washington
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Sep 25, 2013
P1, N=90, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=72 --> 90
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (clinicaltrials.gov) - Sep 25, 2013
P1, N=175, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=72 --> 90 Recruiting --> Active, not recruiting
- | New P2 trial, Surgery, Metastases: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 23, 2013
P2, N=168, Recruiting, Sponsor: National Cancer Institute (NCI)
- Yervoy (ipilimumab) / BMS
New P1 trial, Surgery: SRS (Stereotactic Radiosurgery) Plus Ipilimumab (clinicaltrials.gov) - Sep 23, 2013
P1, N=30, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | Trial completion, Enrollment change, Combination therapy: Novel Adjuvants for Peptide-Based Melanoma Vaccines (clinicaltrials.gov) - Sep 19, 2013
P1, N=19, Completed, Sponsor: University of Southern California
Recruiting --> Active, not recruiting N=72 --> 19 | Recruiting --> Completed
- Trial completion, Combination therapy: Novel Adjuvants for Peptide-Based Melanoma Vaccines (clinicaltrials.gov) - Sep 19, 2013
P1, N=19, Completed, Sponsor: University of Southern California
N=72 --> 19 | Recruiting --> Completed Recruiting --> Completed
- | Yervoy (ipilimumab) / BMS
Enrollment closed: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Sep 9, 2013
P2, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Biomarker, New P1 trial, IO biomarker: BRAF-MEK INHIBITORS IN SEQUENCE WITH IPILIMUMAB FOR BRAF MUTANT MELANOMA (clinicaltrials.gov) - Sep 8, 2013
P1, N=40, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Biomarker, Enrollment open, PD(L)-1 Biomarker, IO biomarker: Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Sep 8, 2013
P1, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / BMS
New P1 trial, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Sep 3, 2013
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (clinicaltrials.gov) - Aug 27, 2013
P1/2, N=24, Completed, Sponsor: California Pacific Medical Center Research Institute
Not yet recruiting --> Recruiting Recruiting --> Completed
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Combination therapy, Metastases: NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Aug 25, 2013
P1, N=27, Recruiting, Sponsor: Ludwig Institute for Cancer Research
Recruiting --> Completed N=18 --> 27
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: CheckMate 069: Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (clinicaltrials.gov) - Aug 20, 2013
P2, N=150, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial initiation date: Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (clinicaltrials.gov) - Aug 4, 2013
P1, N=136, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=18 --> 27 Initiation date: Jan 2009 --> Dec 2009
- |||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Enrollment open, Metastases: PROCLIVITY 02: HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 31, 2013
P4, N=100, Recruiting, Sponsor: Prometheus Laboratories
Initiation date: Jan 2009 --> Dec 2009 Active, not recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (clinicaltrials.gov) - Jul 30, 2013
P2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
New P2 trial, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2013
P2, N=92, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker: E4412: Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jul 9, 2013
P1, N=27, Recruiting, Sponsor: National Cancer Institute (NCI)
- Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 23, 2013
P2, N=8, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting N=200 --> 8
- Yervoy (ipilimumab) / BMS
Enrollment open, Surgery, Metastases: Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 23, 2013
P1, N=28, Recruiting, Sponsor: Northwestern University
N=200 --> 8 Suspended --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 23, 2013
P2, N=8, Completed, Sponsor: Bristol-Myers Squibb
Suspended --> Recruiting Active, not recruiting --> Completed
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Trial initiation date, Combination therapy, Metastases: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=30, Recruiting, Sponsor: Ahmad Tarhini
Active, not recruiting --> Completed Initiation date: Jul 2012 --> Jun 2013
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Enrollment open, Combination therapy, Metastases: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Jun 16, 2013
P=N/A, N=30, Recruiting, Sponsor: Ahmad Tarhini
Initiation date: Jul 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- |||| Yervoy (ipilimumab) / BMS
Monotherapy: Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (clinicaltrials.gov) - Jun 16, 2013
P2, N=72, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Abraxane Plus Bevacizumab Versus Ipilimumab as 1st Line Therapy for BRAFwt Metastatic Melanoma (clinicaltrials.gov) - Jun 13, 2013
P2, N=176, Recruiting, Sponsor: Academic and Community Cancer Research United
- | Yervoy (ipilimumab) / BMS
Enrollment closed, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jun 12, 2013
P2a, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Combination therapy, IO biomarker, Metastases: Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - Jun 10, 2013
P1, N=8, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting N=120 --> 8
- ||||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (clinicaltrials.gov) - Jun 9, 2013
P3, N=700, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=120 --> 8 Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Metastases: Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (clinicaltrials.gov) - May 29, 2013
P3, N=645, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - May 23, 2013
P1, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Jan 2012 --> Aug 2012